Effects of pindolol on serum lipoproteins and postheparin lipolytic activities in hypertensive patients. 1990

N Sasaki, and Y Saito, and M Shinomiya, and T Kanzaki, and Y Ishikawa, and S Mori, and J Kobayashi, and S Murano, and T Nishide, and N Morisaki
Department of Internal Medicine, Kawatetsu Chiba Hospital, Japan.

Thirty-four hyperlipoproteinemic, hypertensive patients received 5 mg of pindolol twice daily for 12 weeks. During pindolol administration, there were significant decreases in serum triglyceride levels and increases in high-density lipoprotein cholesterol (HDL-C) levels, while total cholesterol levels did not change. Serum levels of very-low-density lipoprotein (VLDL) triglyceride and VLDL cholesterol decreased over time as HDL-C increased. There was a significant increase in low-density lipoprotein cholesterol at week 12. Apolipoprotein (apo) A-I, A-II, and B levels did not change during pindolol administration, but apo C-II, C-III, and E levels decreased significantly. Lipoprotein lipase activity in heparin-treated plasma was significantly higher after pindolol administration. The results suggest that the reduction in triglyceride levels and increase in HDL-C after pindolol are partly a response to an increase in the hydrolysis of VLDL resulting from an increase in lipoprotein lipase activity.

UI MeSH Term Description Entries
D006951 Hyperlipoproteinemias Conditions with abnormally elevated levels of LIPOPROTEINS in the blood. They may be inherited, acquired, primary, or secondary. Hyperlipoproteinemias are classified according to the pattern of lipoproteins on electrophoresis or ultracentrifugation. Hyperlipoproteinemia
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008066 Lipolysis The metabolic process of breaking down LIPIDS to release FREE FATTY ACIDS, the major oxidative fuel for the body. Lipolysis may involve dietary lipids in the DIGESTIVE TRACT, circulating lipids in the BLOOD, and stored lipids in the ADIPOSE TISSUE or the LIVER. A number of enzymes are involved in such lipid hydrolysis, such as LIPASE and LIPOPROTEIN LIPASE from various tissues. Lipolyses
D008074 Lipoproteins Lipid-protein complexes involved in the transportation and metabolism of lipids in the body. They are spherical particles consisting of a hydrophobic core of TRIGLYCERIDES and CHOLESTEROL ESTERS surrounded by a layer of hydrophilic free CHOLESTEROL; PHOSPHOLIPIDS; and APOLIPOPROTEINS. Lipoproteins are classified by their varying buoyant density and sizes. Circulating Lipoproteins,Lipoprotein,Lipoproteins, Circulating
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D010869 Pindolol A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638) Prindolol,LB-46,Visken,LB 46,LB46
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

N Sasaki, and Y Saito, and M Shinomiya, and T Kanzaki, and Y Ishikawa, and S Mori, and J Kobayashi, and S Murano, and T Nishide, and N Morisaki
February 1992, Journal of lipid research,
N Sasaki, and Y Saito, and M Shinomiya, and T Kanzaki, and Y Ishikawa, and S Mori, and J Kobayashi, and S Murano, and T Nishide, and N Morisaki
January 1986, Acta medica Scandinavica,
N Sasaki, and Y Saito, and M Shinomiya, and T Kanzaki, and Y Ishikawa, and S Mori, and J Kobayashi, and S Murano, and T Nishide, and N Morisaki
February 1988, The Journal of clinical endocrinology and metabolism,
N Sasaki, and Y Saito, and M Shinomiya, and T Kanzaki, and Y Ishikawa, and S Mori, and J Kobayashi, and S Murano, and T Nishide, and N Morisaki
June 1986, The Journal of sports medicine and physical fitness,
N Sasaki, and Y Saito, and M Shinomiya, and T Kanzaki, and Y Ishikawa, and S Mori, and J Kobayashi, and S Murano, and T Nishide, and N Morisaki
January 1989, Clinical therapeutics,
N Sasaki, and Y Saito, and M Shinomiya, and T Kanzaki, and Y Ishikawa, and S Mori, and J Kobayashi, and S Murano, and T Nishide, and N Morisaki
January 2000, Medical science monitor : international medical journal of experimental and clinical research,
N Sasaki, and Y Saito, and M Shinomiya, and T Kanzaki, and Y Ishikawa, and S Mori, and J Kobayashi, and S Murano, and T Nishide, and N Morisaki
December 1989, Indian journal of experimental biology,
N Sasaki, and Y Saito, and M Shinomiya, and T Kanzaki, and Y Ishikawa, and S Mori, and J Kobayashi, and S Murano, and T Nishide, and N Morisaki
May 1986, Metabolism: clinical and experimental,
N Sasaki, and Y Saito, and M Shinomiya, and T Kanzaki, and Y Ishikawa, and S Mori, and J Kobayashi, and S Murano, and T Nishide, and N Morisaki
February 1988, Atherosclerosis,
N Sasaki, and Y Saito, and M Shinomiya, and T Kanzaki, and Y Ishikawa, and S Mori, and J Kobayashi, and S Murano, and T Nishide, and N Morisaki
June 1972, Israel journal of medical sciences,
Copied contents to your clipboard!